Elafibranor

Phase 3

Ipsen S.A. (IPN.PA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Primary Biliary Cholangitis (PBC)

View Full Landscape

Drug Information

Target Indication

Primary Biliary Cholangitis (PBC)

Clinical Trial

NCT06016842

Last updated: 6/30/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/19/2024

Iqirvo

Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

OrphanConditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IPN.PA

Ipsen S.A.

Pharmaceutical Preparations•Europe•Euronext Paris

Related Pipeline

IPN10200Phase 3

Moderate to Severe Glabellar Lines

Lanreotide autogelPhase 3

Gastroenteropancreatic Neuroendocrine Tumor

CorabotasePhase 3

Cervical Dystonia

lanreotide (Autogel formulation)Phase 3

Diarrhea

OdevixibatPhase 3

Alagille Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts